REFERENCES
- Yanagisawa M. A novel potent vasoconstrictor peptide produced by vascular endothelial cells. Nature 1988; 332: 411–415
- Levin E R. Endothelins. N Engl J Med 1995; 333: 356–363
- Kohan D E. Endothelins in normal and diseased kidney. Am J Kidney Dis 1997; 29: 2–26
- Nakamura T, Ebihara I, Fukui M, Tomino Y, Koide H. Effect of a specific endothelin receptor A antagonist on mRNA levels for extracellular matrix components and growth factors in diabetic glomeruli. Diabetes 1995; 44: 95–899
- Benigni A, Colosio V, Brena C. Unselective inhibition of endothelin receptors reduces renal dysfunction in experimental diabetes. Diabetes 1998; 47: 450–456
- Takahashi K. Elevated plasma endothelin in patients with diabetes mellitus. Diabetologia 1990; 33: 306–310
- Vermes I, Spooren P FMJ, Kalsbeek-Batenburg E M. In addition to von Willebrand factor and urinary albumin excretion, plasma endothelin is an indicator of endothelial dysfunction in diabetes mellitus. Diabetologia 1993; 36: 472–473
- Morise T. Increased plasma levels of immunoreactivity endothelin-1 and von Willebrand factor in type 2 diabetes patients. Diabetes Care 1995; 18: 87–89
- The National High Blood Pressure Education Program Working Group. National high blood pressure education program working group report on hypertension in diabetes. Hypertension 1994; 23: 145–158
- Elliott W J, Stein P P, Black H R. Drug treatment of hypertension in patients with diabetes. Diabetes rev 1995; 3: 477–509
- Molitch M E. Management of early diabetic nephropathy. Am J Med 1997; 102: 392–398
- Lewis E J, Hunsicker L G, Bain R P, Rohde R D. The effect of angiotensin-converting-enzyme inhibition on diabetic nephropathy. The Collaborative Study Group 1993; 329: 1456–1462
- The Microalbuminuria Captopril Study Group. Captopril reduces the risk of nephropathy in IDDM patients with microalbuminuria. Diabetologia 1996; 39: 587–593
- Parving H-H, Rossing P. Calcium antagonists and the diabetic hypertensive patient. Am J Kidney Dis 1993; 21(Suppl. 3)47–52
- Kasiske B L. Effect of antihypertensive therapy on the kidney in patients with diabetes. A metaregression analysis. Ann Intern Med 1993; 118: 129–138
- Weidman P, Bochlen L M, De Courten. Therapeutic efficacy of different antihypertensive drugs in human diabetic nephropathy. An updated meta-analysis. Nephrol Dial Transplant 1995; 10(Suppl. 9)39–45
- Ando K. Presence of immunoreactive endothelin in human plasma. FEBS Lett 1989; 245: 164–166
- Hills M, Armitage P. The two-period cross-over clinical trial. Br J Clin Pharmac 1979; 8: 7–20
- Ferri C. Circulating endothelin-1 levels in lean non-insulin-dependent diabetic patients. Influence of ACE inhibition. Am J Hypertens 1995; 8: 40–47
- Kurokawa K. Regulation of cortical collecting duct function. Effect of endothelin. Am Heart J 1993; 125: 582–588
- Rabelink T J. Effects of endothelin-1 on renal function in humans. Implications for physiology and pathophysiology. Kidney Int 1994; 46: 376–381
- Modesti P A. Increased renal endothelin formation is associated with sodium retention and increased free water clearance. Am J Physiol 1998; 275: H1070–H1077
- van Schaik B A, van Nistelrooy E A, Geyskes G G. Antihypertensive and renal effects of nicardipine. Br J Clin Pharmacol 1984; 18: 57–63
- Holdaas H. Contrasting effects of lisinopril and nifedipine on albuminuria and tubular transport functions in insulin dependent diabetes with nephropathy. J Intern Med 1991; 229: 163–170
- Larochelle P. Renal tubular effects of calcium antagonists. Kidney Int 1992; 41(Suppl 36)S49–S53
- Demaire B K, Bakris L G. Effects of different classes of calcium antagonist on proteinuria in diabetic subjects. Ann Intern Med 1995; 155: 2150–2156
- Rossing P. Differences between nisoldipine and lisinopril on glomerular filtration rates and albuminuria in hypertensive IDDM patients with diabetic nephropathy during the first year of treatment. Diabetes 1997; 46: 481–487